logo

For the Inventor, By the Inventor

Kasterlee, Belgium

Jacobus Alphonsus Josephus Van Dun

This inventor holds 18 USPTO granted patents and 2 published patent applications and 7 EPO patents. Top assignees: Janssen Pharmaceutica Nv, Janssen Pharmaceutica, Other. Active years: 2007-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jacobus Alphonsus Josephus Van Dun. Retrieved from https://idiyas.com/inventor/jacobus-alphonsus-josephus-van-dun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 22.2


Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 70(Granted Patents)


Location History:

  • Tielen, BE (2013)
  • Beerse, BE (2015)
  • Kasterlee, BE (2007 - 2018)

Company Filing History:

goldMedal16 out of 2,101 
 
Janssen Pharmaceutica Nv
 patents
silverMedal1 out of 32 
 
Janssen Pharmaceutica
 patents
bronzeMedal1 out of 834,570 
Other
 patents

Years Active: 2007-2018

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents
1. 10150757 - Quinazolinone derivatives as PARP inhibitors (2018-12-11),
2. 9522905 - Quinazolinone derivatives as PARP inhibitors (2016-12-20),
3. 9255080 - Quinazolinedione derivatives as PARP inhibitors (2016-02-09),
4. 9115084 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors (2015-08-25),
5. 8623884 - Quinazolinedione derivatives as PARP inhibitors (2014-01-07),
6. 8623872 - Quinazolinone derivatives as PARP inhibitors (2014-01-07),
7. 8524714 - 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors (2013-09-03),
8. 8450486 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors (2013-05-28),
9. 8188103 - Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors (2012-05-29),
10. 8071612 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors (2011-12-06),
11. 7928104 - 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors (2011-04-19),
12. 7879857 - 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors (2011-02-01),
13. 7875621 - Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors (2011-01-25),
14. 7855207 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors (2010-12-21),
15. 7803795 - Phthalazine derivatives as parp inhibitors (2010-09-28),

Title: Jacobus Alphonsus Josephus Van Dun: A Pioneer in Pharmaceutical Innovations

Introduction

Jacobus Alphonsus Josephus Van Dun is a notable inventor based in Kasterlee, Belgium. He has made significant contributions to the field of pharmaceuticals, holding a total of 18 patents. His work primarily focuses on developing innovative compounds that serve as therapeutic agents.

Latest Patents

Among his latest patents are the quinazolinone derivatives as PARP inhibitors. These inventions provide compounds of formula (I) and detail their use as PARP inhibitors, along with pharmaceutical compositions that include these compounds. The specific meanings of R, R, R, L, X, Y, and Z are defined within the patent documentation, showcasing the complexity and potential of his work.

Career Highlights

Jacobus has had a distinguished career, working with prominent companies such as Janssen Pharmaceutica NV. His expertise in pharmaceutical research has led to groundbreaking advancements in drug development and therapeutic applications.

Collaborations

Throughout his career, Jacobus has collaborated with esteemed colleagues, including Walter Boudewijn Leopold Wouters and Maria Victorina Francisca Somers. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Jacobus Alphonsus Josephus Van Dun stands out as a significant figure in the pharmaceutical industry, with a strong portfolio of patents and collaborations that highlight his contributions to medical science. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…